The six-month FDA review timeline sets a catalyst date around December 2026. Monitor for FDA acceptance of the resubmissions and any advisory committee meetings. Positive outcome would remove the key overhang from the Reykjavik facility issues and validate the manufacturing turnaround, likely driving significant upside for ALVO.
Price Chart
Executive Summary
Alvotech resubmitted BLAs to the FDA for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar) after responding to a Post-Application Action Letter and completing a May 2026 cGMP surveillance inspection at its Reykjavik facility. The FDA is expected to conduct a six-month review, making a decision by late 2026. This is a critical regulatory milestone that could unlock two major U.S. biosimilar launches and validates manufacturing improvements.
Key Facts
- Alvotech resubmitted BLAs for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar) to the FDA.
- Resubmissions follow response to FDA's Post-Application Action Letter (PAAL) and a May 2026 cGMP surveillance inspection.
- FDA expected to conduct a six-month review of the resubmitted applications.
- AVT05 and AVT06 are partnered with Teva for U.S. commercialization; AVT03 (denosumab biosimilar) is partnered with Dr. Reddy's.
- AVT05 and AVT06 are already approved in multiple global markets including the EEA, UK, Japan, and Canada.
Financial Impact
U.S. market access for two high-value biosimilars (Simponi ~$2B+ annual U.S. sales; Eylea ~$6B+ annual U.S. sales). Approval would unlock significant revenue streams via Teva partnership.
Risk Factors
- FDA may issue a Complete Response Letter if the manufacturing facility improvements are deemed insufficient.
- Competitive biosimilar landscape (e.g., other Eylea biosimilars) could erode peak revenue potential.
- Six-month review timeline is an estimate; delays could push approval into 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 press releases from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306550 |
| PRESS-RELEASE Data (Synthetic) | press-3306551 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $5.12 | awaiting T+20 | — | $4.63 (−9.57%) |
Oct 14, 2026 13d ago | 6-K | $5.17 | awaiting T+20 | — | $4.63 (−10.44%) |
Oct 7, 2026 20d ago | 6-K | $5.85 | awaiting T+20 | — | $4.63 (−20.85%) |
Oct 5, 2026 22d ago | 6-K | $6.11 | awaiting T+20 | — | $4.63 (−24.22%) |
Oct 5, 2026 22d ago | Press Release | $6.11 | awaiting T+20 | — | $4.63 (−24.22%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.63 (−10.79%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.63 (+4.51%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.63 (−8.43%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.63 (+31.16%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.63 (+33.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers